Teduglutide

Teduglutide is a recombinant analog of human glucagon-like peptide-2 (GLP-2) and the first GLP-2 receptor agonist approved for clinical use in the treatment of short bowel syndrome associated with intestinal failure (SBS-IF). The compound differs from native human GLP-2 by a single amino acid substitution: glycine replaces alanine at position 2 from the N-terminus, eliminating the dipeptidyl peptidase-IV (DPP-IV) cleavage site and extending the plasma elimination half-life from approximately 7 minutes (native GLP-2) to approximately 2 to 3 hours after subcutaneous administration [1, 2]. This modification preserves full agonist activity at the GLP-2 receptor (GLP-2R), a class B G-protein-coupled receptor expressed on intestinal subepithelial myofibroblasts, enteric neurons, and enteroendocrine cells, while enabling once-daily subcutaneous dosing at 0.05 mg/kg body weight.

The intestinotrophic actions of teduglutide are mediated through GLP-2R activation on subepithelial myofibroblasts, which triggers downstream release of insulin-like growth factor-1 (IGF-1), epidermal growth factor (EGF), and keratinocyte growth factor (KGF) [3, 4]. These paracrine mediators drive crypt cell proliferation, inhibit enterocyte apoptosis, increase villus height, enhance mucosal barrier function, slow gastric emptying, reduce gastric acid secretion, and increase mesenteric blood flow [5]. The composite physiological effect is an expansion of absorptive intestinal surface area and an improvement in the efficiency of fluid and nutrient absorption in patients with shortened bowel.

Clinical development centered on the pivotal Phase 3 STEPS trial (Study of Teduglutide Effectiveness in Parenteral Nutrition-Dependent Short-Bowel Syndrome Subjects), in which 86 adult SBS-IF patients were randomized to teduglutide 0.05 mg/kg or placebo for 24 weeks [6]. The primary endpoint (20 to 100 percent reduction in parenteral support volume at weeks 20 and 24) was met by 63 percent of teduglutide-treated patients compared to 30 percent of placebo-treated patients (P = 0.002). Three teduglutide-treated patients achieved complete enteral autonomy (full independence from parenteral support). Long-term extension studies (STEPS-2, STEPS-3) demonstrated sustained reductions in parenteral support requirements over 30 months or more, with additional patients achieving enteral autonomy on continued treatment [7, 8].

Teduglutide received European Commission marketing authorization as Revestive in August 2012, United States Food and Drug Administration (FDA) approval as Gattex in December 2012 for adult SBS-IF patients dependent on parenteral support, and FDA pediatric indication expansion in May 2019 for patients one year of age and older [9, 10]. The compound was developed by NPS Pharmaceuticals (subsequently acquired by Shire, then Takeda), with Takeda holding global commercial rights.

The principal safety concerns are the trophic effects of sustained GLP-2R stimulation on intestinal epithelium. Colorectal polyps have been reported in clinical trials and postmarketing surveillance at rates higher than placebo, necessitating colonoscopy within 6 months before treatment initiation, after 1 year of treatment, and every 5 years thereafter [11]. Intestinal obstruction, biliary and pancreatic disease, and fluid overload from increased intestinal absorption are additional monitored risks. Common adverse events at the reported research dose ranges include abdominal pain (28 percent), nausea (26 percent), injection site reactions (26 percent), abdominal distension (17 percent), and headache (16 percent) [12].

This monograph reviews the chemistry, amino acid sequence, and DPP-IV resistance mechanism of teduglutide; the discovery of GLP-2 as an intestinotrophic factor and the development trajectory from preclinical demonstration through registration; the molecular pharmacology of GLP-2R signaling and downstream trophic mediators; the pharmacokinetic profile including absorption, distribution, metabolism, and elimination; the preclinical evidence in rodent models of SBS, mucositis, and colitis; the clinical evidence base across the STEPS trial series and pediatric studies; sourcing and quality verification considerations; reconstitution and handling; stack interaction considerations including effects on oral medication absorption; the adverse event and safety profile with emphasis on colorectal polyp risk; and a comparative assessment of five alternative GLP-2R agonists or intestinal trophic agents (glepaglutide, apraglutide, native GLP-2, growth hormone with glutamine, and somatropin) against teduglutide on five competency standards.